Skip to main content

Table 6 Prediction of clinical activity status by genotype at each of 19 genetic polymorphisms: all response-evaluable patients with genetic polymorphism data and status = benefit or non-benefit.

From: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Gene

Polymorphism

N

DF

P-value

OR: Genotype

1/2 vs 1/1

OR: Genotype

2/2 vs 1/1

     

Estimate

95% CI

Estimate

95% CI

BTNL2

rs2076530

56

2

0.48

0.40

0.08, 1.93

0.81

0.12, 5.25

CCR5

CCR5d32

57

2

0.54

0.41

0.04, 3.83

0.00

0.00, Inf

CCR5

rs1799987

57

2

0.80

0.76

0.17, 3.39

1.35

0.25, 7.35

CD86

rs1129055

57

2

0.11

1.92

0.50, 7.38

0.00

0.00, Inf

CD86

rs2681417

55

1

0.52

2.39

0.18, 31.0

NA

NA, NA

CTLA4

rs11571317

57

1

0.78

0.73

0.07, 7.25

NA

NA, NA

CTLA4

rs1863800

55

2

0.06

0.35

0.08, 1.45

0.00

0.00, Inf

CTLA4

rs231775

56

2

0.05

0.43

0.07, 2.73

3.75

0.72, 19.42

CTLA4

rs3087243

55

2

0.07

0.39

0.09, 1.62

0.00

0.00, Inf

CTLA4

rs4553808

56

2

0.08

0.19

0.02, 1.76

3.25

0.37, 28.28

IFNAR1

rs2257167

57

2

0.98

0.93

0.23, 3.80

1.24

0.10, 14.60

IFNAR2

rs7279064

57

2

0.59

0.83

0.22, 3.15

0.00

0.00, Inf

IFNG

rs2069705

57

2

0.79

0.71

0.18, 2.82

0.50

0.05, 5.31

IFNG

rs2430561

56

2

0.67

1.22

0.20, 7.31

2.36

0.30, 18.72

IL23R

rs1004819

57

2

0.95

0.81

0.19, 3.37

0.97

0.14, 6.52

IL23R

rs11209026

57

1

0.40

0.42

0.05, 3.93

NA

NA, NA

IL23R

rs2201841

56

2

0.82

0.64

0.15, 2.65

0.80

0.07, 9.43

IL23R

rs7517847

56

2

0.35

2.33

0.50, 10.85

0.67

0.06, 7.77

PTPN22

rs2476601

57

1

0.95

0.93

0.09, 9.69

NA

NA, NA

  1. 1/1 = major-allele homozygote; 1/2 = heterozygote; 2/2 = minor-allele homozygote.
  2. CI = Confidence Interval.
  3. DF = degrees of freedom for likelihood-ratio test (LRT).
  4. Inf = infinite.
  5. N = number of patients with non-missing genotypes.
  6. OR = odds ratio comparing the odds of Status = Benefit between two genotype classes. OR > 1 means that the odds of Benefit were greater for class 1/2 or 2/2 than for class 1/1.
  7. NA = not estimable.
  8. P-value is for a logistic regression LRT of whether both (if > 1 estimable) odds ratios = 1.